APLS
Price
$19.82
Change
+$0.07 (+0.35%)
Updated
Jul 18, 01:44 PM (EDT)
Capitalization
2.52B
24 days until earnings call
PGEN
Price
$1.75
Change
-$0.07 (-3.85%)
Updated
Jul 18, 04:59 PM (EDT)
Capitalization
537.23M
24 days until earnings call
Interact to see
Advertisement

APLS vs PGEN

Header iconAPLS vs PGEN Comparison
Open Charts APLS vs PGENBanner chart's image
Apellis Pharmaceuticals
Price$19.82
Change+$0.07 (+0.35%)
Volume$2.91K
Capitalization2.52B
Precigen
Price$1.75
Change-$0.07 (-3.85%)
Volume$34.19K
Capitalization537.23M
APLS vs PGEN Comparison Chart in %
Loading...
APLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
APLS vs. PGEN commentary
Jul 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APLS is a Hold and PGEN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 18, 2025
Stock price -- (APLS: $20.04 vs. PGEN: $1.82)
Brand notoriety: APLS and PGEN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APLS: 72% vs. PGEN: 83%
Market capitalization -- APLS: $2.52B vs. PGEN: $537.23M
APLS [@Biotechnology] is valued at $2.52B. PGEN’s [@Biotechnology] market capitalization is $537.23M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.62B to $0. The average market capitalization across the [@Biotechnology] industry is $2.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APLS’s FA Score shows that 0 FA rating(s) are green whilePGEN’s FA Score has 0 green FA rating(s).

  • APLS’s FA Score: 0 green, 5 red.
  • PGEN’s FA Score: 0 green, 5 red.
According to our system of comparison, PGEN is a better buy in the long-term than APLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APLS’s TA Score shows that 6 TA indicator(s) are bullish while PGEN’s TA Score has 5 bullish TA indicator(s).

  • APLS’s TA Score: 6 bullish, 3 bearish.
  • PGEN’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, APLS is a better buy in the short-term than PGEN.

Price Growth

APLS (@Biotechnology) experienced а +2.61% price change this week, while PGEN (@Biotechnology) price change was -4.71% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.34%. For the same industry, the average monthly price growth was +13.98%, and the average quarterly price growth was +35.38%.

Reported Earning Dates

APLS is expected to report earnings on Nov 10, 2025.

PGEN is expected to report earnings on Nov 12, 2025.

Industries' Descriptions

@Biotechnology (+3.34% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
APLS($2.52B) has a higher market cap than PGEN($537M). PGEN YTD gains are higher at: 62.500 vs. APLS (-37.198). PGEN has higher annual earnings (EBITDA): -154.85M vs. APLS (-176.08M). APLS has more cash in the bank: 358M vs. PGEN (80.2M). PGEN has less debt than APLS: PGEN (5.42M) vs APLS (470M). APLS has higher revenues than PGEN: APLS (776M) vs PGEN (4.2M).
APLSPGENAPLS / PGEN
Capitalization2.52B537M469%
EBITDA-176.08M-154.85M114%
Gain YTD-37.19862.500-60%
P/E RatioN/AN/A-
Revenue776M4.2M18,472%
Total Cash358M80.2M446%
Total Debt470M5.42M8,676%
FUNDAMENTALS RATINGS
APLS vs PGEN: Fundamental Ratings
APLS
PGEN
OUTLOOK RATING
1..100
918
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
70
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
6339
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PGEN's Valuation (70) in the null industry is in the same range as APLS (71) in the Medical Distributors industry. This means that PGEN’s stock grew similarly to APLS’s over the last 12 months.

PGEN's Profit vs Risk Rating (100) in the null industry is in the same range as APLS (100) in the Medical Distributors industry. This means that PGEN’s stock grew similarly to APLS’s over the last 12 months.

APLS's SMR Rating (98) in the Medical Distributors industry is in the same range as PGEN (100) in the null industry. This means that APLS’s stock grew similarly to PGEN’s over the last 12 months.

PGEN's Price Growth Rating (39) in the null industry is in the same range as APLS (63) in the Medical Distributors industry. This means that PGEN’s stock grew similarly to APLS’s over the last 12 months.

PGEN's P/E Growth Rating (100) in the null industry is in the same range as APLS (100) in the Medical Distributors industry. This means that PGEN’s stock grew similarly to APLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
APLSPGEN
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
89%
Momentum
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 9 days ago
84%
Declines
ODDS (%)
Bearish Trend 19 days ago
79%
Bearish Trend 2 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
88%
Aroon
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
APLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PHLCX11.93N/A
N/A
PGIM Jennison Health Sciences C
CMNWX82.48N/A
N/A
Principal Capital Appreciation A
MSQLX11.33N/A
N/A
Morgan Stanley Inst International Eq L
GMVRX16.18N/A
N/A
Goldman Sachs Small/Mid Cap Equity R
EEMHX9.18N/A
N/A
MFS Emerging Markets Equity Research R6

APLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, APLS has been loosely correlated with ROIV. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if APLS jumps, then ROIV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APLS
1D Price
Change %
APLS100%
+1.47%
ROIV - APLS
48%
Loosely correlated
+0.95%
DNLI - APLS
47%
Loosely correlated
-2.29%
EYPT - APLS
46%
Loosely correlated
+2.39%
BPMC - APLS
44%
Loosely correlated
+0.14%
KYMR - APLS
44%
Loosely correlated
+1.85%
More